BI 639667

Cat. No.:	HY-120588
CAS No.:	1295298-26-8
Molecular Formula:	$C_{22}H_{18}FN_5O_3S$
Molecular Weight:	451.47
Target:	CCR
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (22.15 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2150 mL	11.0749 mL	22.1499 mL
	5 mM	0.4430 mL	2.2150 mL	4.4300 mL
	10 mM	0.2215 mL	1.1075 mL	2.2150 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1 mg/mL (2.21 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1 mg/mL (2.21 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1 mg/mL (2.21 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BI 639667 (compound 19n), a third azaindazole series compound, is a CCR1 antagonist, with an IC_{50} of 1.8 nM in Ca^{2+} flux assay[1].

IC_{50} & Target

CCR1
1.8 nM (IC_{50}, in Ca^{2+} flux assay)

REFERENCES

[1]. Harcken C, et al. Identification of novel azaindazole CCR1 antagonist clinical candidates. Bioorg Med Chem Lett. 2019 Feb 1;29(3):441-448.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA